FRANK JONES Email

President and Chief Scientific Officer . Etubics

Current Roles

Employees:
9
Revenue:
$1.4M
About
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company. The Company is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. The Company’s products have been developed to overcome three significant limitations associated with existing adenovirus based products: i) ineffectiveness in the presence of pre-existing immunity; ii) inability to immunize multiple times against the same disease; and, iii) inability to immunize against multiple diseases in the same person. Benefits of the Etubics Platform products include the following: • Safe and Thoroughly Studied including human trials • Effective in the Presence of Pre-Existing Immunity • CMI Response • Rapid Development • Diverse Product Opportunities The Company has completed Phase I/IIa clinical trials with its lead product, ETBX-011 an immunotherapeutic to treat colorectal cancer. To date, the Company has been very encouraged by the clinical data for ETBX-011 and no safety issues or serious adverse effects (SAE) have been reported in both animal and human studies.
Etubics Address
410 West Harrison Street
Seattle, WA
United States
Etubics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.